These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 30064702

  • 1. Effect of amorphous phase separation and crystallization on the in vitro and in vivo performance of an amorphous solid dispersion.
    Knopp MM, Wendelboe J, Holm R, Rades T.
    Eur J Pharm Biopharm; 2018 Sep; 130():290-295. PubMed ID: 30064702
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of polymer type and drug dose on the in vitro and in vivo behavior of amorphous solid dispersions.
    Knopp MM, Chourak N, Khan F, Wendelboe J, Langguth P, Rades T, Holm R.
    Eur J Pharm Biopharm; 2016 Aug; 105():106-14. PubMed ID: 27212472
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phase Behavior of Ritonavir Amorphous Solid Dispersions during Hydration and Dissolution.
    Purohit HS, Taylor LS.
    Pharm Res; 2017 Dec; 34(12):2842-2861. PubMed ID: 28956218
    [Abstract] [Full Text] [Related]

  • 9. Amorphous solid dispersion of nisoldipine by solvent evaporation technique: preparation, characterization, in vitro, in vivo evaluation, and scale up feasibility study.
    Chavan RB, Lodagekar A, Yadav B, Shastri NR.
    Drug Deliv Transl Res; 2020 Aug; 10(4):903-918. PubMed ID: 32378174
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Elucidating the effect of crystallization on drug release from amorphous solid dispersions in soluble and insoluble carriers.
    Ojo AT, Ma C, Lee PI.
    Int J Pharm; 2020 Dec 15; 591():120005. PubMed ID: 33132149
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Solubility advantage from amorphous etoricoxib solid dispersions.
    Dani P, Puri V, Bansal AK.
    Drug Dev Ind Pharm; 2014 Jan 15; 40(1):92-101. PubMed ID: 23301771
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Anomalous dissolution behavior of celecoxib in PVP/Isomalt solid dispersions prepared using spray drier.
    Ghanavati R, Taheri A, Homayouni A.
    Mater Sci Eng C Mater Biol Appl; 2017 Mar 01; 72():501-511. PubMed ID: 28024614
    [Abstract] [Full Text] [Related]

  • 19. Effect of Variability of Physical Properties of Povidone K30 on Crystallization and Drug-Polymer Miscibility of Celecoxib-Povidone K30 Amorphous Solid Dispersions.
    Phadke C, Sharma J, Sharma K, Bansal AK.
    Mol Pharm; 2019 Oct 07; 16(10):4139-4148. PubMed ID: 31454247
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.